A Phase 4 interventional study of Granulocyte Colony-Stimulating Factor (G-CSF) and Omission of Granulocyte Colony-Stimulating Factor (G-CSF) in Early-stage Breast Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing filgrastim in Breast Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Breast Neoplasms.
Among the 31 studies testing filgrastim in Breast Neoplasms, this one is the 7th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 4, and was the 31st registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →1 of the 31 studies testing filgrastim in Breast Neoplasms is open now, in 1 country.
By country, each count listing its studies:
Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 7 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 242 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 27 interventional studies. Of the 29 that completed or were terminated, 10 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 31 have an industry lead sponsor. The 10 most frequent:
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
44 studies in Breast Neoplasms by Ottawa Hospital Research Institute: 4 open now, 7 under way, none of them phase 3. Of 27 finished, 6 (22%) have results posted.
Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 8th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2023, is one of 20 in phase 4, and was the 41st registered.
Ottawa Hospital Research Institute’s Breast Neoplasms studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing filgrastim in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ottawa Hospital Research Institute’s 44 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Optimal curative chemotherapy treatment in the early-stage setting for breast cancer patients can reduce the risk of recurrence and result in improvement in breast cancer survival. The pivotal Cancer and Leukemia Group B (CALGB) 9741 clinical trial demonstrated improved efficacy from administering 4 cycles of adriamycin and cyclophosphamide (AC) followed by 4 cycles of paclitaxel using a dose-dense schedule every 2-weeks instead of every 3 weeks in patients with high-risk early-stage breast cancer. It has since become a widely accepted standard care treatment option. Granulocyte colony-stimulating factor (G-CSF) such as filgrastim (FIL) and pegfilgrastim (PEG) are key supportive medications used with the dose-dense regimen to facilitate timely recovery of neutrophil count before the next cycle of treatment. However, G-CSF is associated with increased bone pain after chemotherapy (up to 40%) and drug-induced fever, which can result in additional clinical or emergency room visits. Clinicians have questioned if primary prophylactic G-CSF use is necessary with paclitaxel in the dose-dense regimen and the risk of hematological toxicity, such as the risk of low neutrophils and the risk of infection is lower with paclitaxel. Results from two retrospective studies suggest that it is safe and feasible to omit G-CSF during the paclitaxel portion of the DD-AC/T regimen. Based on the current trial data, there is a stong suggestion that it is safe, feasible and likely preferable to omit G-CSF during the paclitaxel portion of DD-AC/T chemotherapy. Given the majority of chemotherapy dose delays are related to issues such as bone pain (from G-CSF and paclitaxel) and peripheral neuropathy (from paclitaxel), and this may even be exacerbated by the use of G-CSF, it is anticipated that omitting G-CSF during paclitaxel chemotherapy may improve completion rates while improving health related quality of life (HR-QoL). Therefore, the researchers propose a randomized study to further evaluate patient-reported bone pain and HR-QoL from the omission of primary prophylactic G-CSF use during the paclitaxel portion of DD-AC/T chemotherapy while demonstrating supportive evidence that omitting G-CSF is safe and feasible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receive G-CSF injections (either filgrastim or pegfilgrastim) after each cycle of paclitaxel chemotherapy.
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Omission of G-CSF injections after each cycle of paclitaxel chemotherapy.
Drug: Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
Also known as: Filgrastim, Pegfilgrastim
Drug pages: Granulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FilgrastimStudies of FilgrastimFilgrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
Patient-reported bone pain during cycle 1 of paclitaxel
The primary outcome is patient-reported bone pain from day 1 to 5 during cycle 1 of paclitaxel chemotherapy. The total measure of bone pain over the five days will be summarized by the area under the curve (AUC) using the trapezoidal quadrature method for patients reported daily pain score from day 1 to 5 during cycle 1 of paclitaxel chemotherapy. Day 1 being the morning after first dose of G-CSF injection, or 48 hours after chemotherapy injection in the No G-CSF arm. The daily pain score ranges from 0-40. Peak pain is defined as the maximum pain rating over day 1 to day 5. To reiterate the scoring system, every morning, patients are asked to rate the most severe pain they experienced in the last 24 hours on a visual analogue scale (VAS) from 0 (no pain) to 10 (pain as bad as you can imagine). The X axis of the AUC represents time (i.e., days) and the Y axis represents pain severity (0-10).
Time frame: At the end of cycle 1 of paclitaxel chemotherapy (each cycle is 14 days)
Patient-reported bone pain across all paclitaxel cycles
Bone pain mean AUC across all cycles of paclitaxel chemotherapy. The total measure of bone pain over the five days will be summarized by the area under the curve (AUC) using the trapezoidal quadrature method for patients reported daily pain score from day 1 to 5 during all cycles of paclitaxel chemotherapy. Day 1 being the morning after first dose of G-CSF injection, or 48 hours after chemotherapy injection in the No G-CSF arm. The daily pain score ranges from 0-40. Peak pain is defined as the maximum pain rating over day 1 to day 5. To reiterate the scoring system, every morning, patients are asked to rate the most severe pain they experienced in the last 24 hours on a visual analogue scale (VAS) from 0 (no pain) to 10 (pain as bad as you can imagine). The X axis of the AUC represents time (i.e., days) and the Y axis represents pain severity (0-10).
Time frame: After each of the paclitaxel chemotherapy cycles (each cycle is 14 days)
Peak bone pain experienced
Peak bone pain experienced across all cycles of paclitaxel. Measured by the patient reported daily pain score from days 1 to 5 during all 4 cycles of paclitaxel chemotherapy. Bone pain is measured on a scale ranging from 0-10, 0 being no pain and 10 being the worst possible pain.
Time frame: Days 1 to 5 of the each of the paclitaxel chemotherapy cycles (each cycle is 14 days)
Patient health-related quality of life
Patient Health-Related Quality of Life (HR-QoL) based on the EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire.
Time frame: Through study completion, average of 12 weeks
Rates of completion of 4 cycles of paclitaxel
Rates of completion of 4 cycles of paclitaxel chemotherapy within 7 weeks (days 1 cycle 5 to day 1 cycle 8 of chemotherapy)
Time frame: Through study completion, average of 12 weeks
Dose-intensity of paclitaxel chemotherapy
Dose intensity of paclitaxel (mg/m2/wk) chemotherapy. Dose intensity is a measure of a dose delay/dose reduction and premature chemotherapy discontinuation.
Time frame: Through study completion, average of 12 weeks
Incidence of febrile neutropenia/neutropenia
Incidences of febrile neutropenia/neutropenia will be collected using pretreatment bloodwork that is routinely performed before each chemotherapy cycle. For this study, febrile neutropenia (FN) is defined as a one-time oral temperature greater or equal to 38.3 degrees Celsius (approximately 100.9 Fahrenheit) or a sustained temperature equal or greater than 38 degrees Celsius for 1 or more hours in a patient who has an absolute neutrophil count of less than 500 cells/microliter or an absolute neutrophil count expected to decrease to less than 500 cells/microliter within a 48-hour period.
Time frame: Through study completion, average of 12 weeks
Incidence of treatment-related hospitalizations/ER visits
The number of treatment-related hospitalizations and emergency room visits that occur from the start of paclitaxel chemotherapy to 1 month after the last paclitaxel chemotherapy cycle
Time frame: Through study completion, average of 12 weeks
Healthcare resource utilization: Emergency Room Visits
The number of emergency room visits that occur will be collected.
Time frame: Through study completion, average of 12 weeks
Healthcare resource utilization: Planned and Unplanned Provider Visits
The number of planned and unplanned provider clinic visits, including visits to stretcher bay will be collected.
Time frame: Through study completion, average of 12 weeks
Healthcare resource utilization: Phone Calls and Emails
The number of phone calls and emails to patient support line provider (reported by the patient) will be collected.
Time frame: Through study completion, average of 12 weeks
Cost-effectiveness ratios
There will be a cost-utility analysis comparing the differences in cost and quality-adjusted life years (QALY) between omitting G-CSF and standard G-CSF use. The statistical analysis will be conducted in accordance with current guidelines for clinical and cost-effectiveness analysis alongside randomized clinical trials (RCTs). Health utility values will be derived from EQ-5D-5L scores using the published mapping algorithm.
Time frame: Through study completion, average of 12 weeks
Incidence of chemotherapy-related mortality
Deaths from start of chemotherapy to one month after completion of last chemotherapy cycle
Time frame: Through study completion, average of 12 weeks
Rate of secondary G-CSF or antibiotic use
Rates of added G-CSF use for both randomization arms will be collected. As well as the addition of antibiotic use.
Time frame: Through study completion, average of 12 weeks
Started Apr 2023 (actual). Primary completion is estimated for Oct 2026, 42 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 42 months is close to that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Filgrastim
Ottawa Hospital Research Institute →